德州扑克黑幕中关村|德州扑克单挑技巧规律
    最新公告
    自貿區政策欄目近日開通,詳情請點擊首頁相關模塊。
 

相關鏈接

訪問我們的下載中心以獲取相關的下載內容

藥明康德董事長李革博士榮獲CPhI“2019年度CEO”

發布時間:2019-11-15

藥明康德/報道

藥明康德董事長李革博士榮獲CPhI“2019年度CEO”

2019年11月11日——全球知名的世界制藥原料博覽會(CPhI)日前公布2019年度獎項(CPhI Pharma Awards)評選結果,藥明康德董事長兼首席執行官李革博士憑借為全球生物醫療研發領域做出的卓越貢獻,榮獲“年度CEO”稱號。

CPhI是世界上最大的醫藥行業盛會之一,今年的CPhI全球大會(CPhI Worldwide)吸引了超過45,000名業內人士參會。CPhI年度獎項旨在表彰那些堅持不懈、開拓創新,為推動行業發展做出重要貢獻的企業與個人。獎項評審委員會獨立客觀,由全球多位資深專家組成。

評委會表示,在李革博士的帶領下,藥明康德已成為全球醫藥創新領域備受尊崇的賦能者,為醫療健康行業的發展做出了卓越的貢獻。如今,藥明康德開放式、一體化賦能平臺正承載著全球30多個國家,3700多個合作伙伴的研發創新項目,不斷加速新藥研發進程,為患者帶來突破性的治療方案。

“我很高興獲此殊榮,也特別感謝評委會對藥明康德全球化賦能平臺的認可,”藥明康德董事長兼首席執行官李革博士表示,“我們非常榮幸能夠幫助全球創新合作伙伴提升研發效率,讓更多新藥、好藥早日進入市場,造福全球病患。”

關于藥明康德

藥明康德(股票代碼:603259.SH/2359.HK)為全球生物醫藥行業提供全方位、一體化的新藥研發和生產服務。通過賦能全球制藥、生物科技和醫療器械公司,藥明康德致力于推動新藥研發進程,為患者帶來突破性的診療方案。本著以研究為首任,以客戶為中心的宗旨,藥明康德通過高性價比和高效的研發服務,助力客戶提升研發效率,服務范圍涵蓋化學藥研發和生產、細胞及基因療法研發生產、醫療器械測試等領域。目前,藥明康德的賦能平臺正承載著來自全球30多個國家的3700多家合作伙伴的研發創新項目,致力于將更多新藥、好藥帶給全球病患,早日實現“讓天下沒有難做的藥,難治的病”的愿景。更多信息,請訪問公司網站:www.wuxiapptec.com

Dr. Ge Li Awarded “CEO of the Year” at CPhI Worldwide 2019

November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, announced today that its Chairman and CEO Dr. Ge Li was awarded “CEO of the Year” at the CPhI Worldwide 2019, a top pharmaceutical event uniting over 45,000 professionals worldwide.

The 2019 CPhI Pharma Awards recognize the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward. Its Judging Panel is comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.

Dr. Ge Li was chosen for his significant contribution to the global biopharma R&D industry. “Under his leadership, WuXi AppTec has become a highly respected contributor to global healthcare innovation. The company is enabling more than 3,700 customers and partners in more than 30 countries by offering open-access capabilities and services, accelerating the discovery and development of new medicines for patients around the world.”

“I’m honored by this award and its recognition of WuXi’s global platform,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “It’s been our great privilege to serve our innovative partners around the world and help bring some of the most needed medicines closer to patients.”

About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com.


信息來源:藥明康德

德州扑克黑幕中关村 cba新浪体育 上海快3 广东26选5 wnba比分结果查询 福彩 天津十一选五 nba比分 3D 亿客隆彩票 江西快三 e球彩 训盈网球比分扳 3d试机号 北单比分直播最快最准 秒速时时彩 11选5